Indrayani Biotech Intrinsic Value
Indrayani Biotech (INDRANIB) median intrinsic value is ₹15.65 from 9 valuation models (range ₹6–₹23), vs current price ₹9.36 — +67.2% upside (Trading Below Calculated Value), margin of safety 40.2%. Check Indrayani Biotech marketcap in USD to track the company's total market size over time.
INDRANIB Valuation Methods Summary — DCF, Graham Number & P/E
Indrayani Biotech intrinsic value across 9 models vs current price ₹9.36 — upside/downside and value range per method. For current market price and key ratios, visit INDRANIB share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹11.52 | ₹9.22 - ₹13.82 | +23.1% | EPS: ₹0.96, Sector P/E: 12x |
| Book Value Method | asset | ₹15.87 | ₹14.28 - ₹17.46 | +69.6% | Book Value/Share: ₹15.87, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹18.72 | ₹16.85 - ₹20.59 | +100.0% | Revenue/Share: ₹33.91, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹15.65 | ₹14.09 - ₹17.22 | +67.2% | EBITDA: ₹12.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹23.40 | ₹18.72 - ₹28.08 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹6.14 | ₹5.53 - ₹6.75 | -34.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹7.91 | ₹7.12 - ₹8.70 | -15.5% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹8.70 | ₹7.83 - ₹9.57 | -7.1% | ROE: 5.5%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹18.51 | ₹16.66 - ₹20.36 | +97.8% | EPS: ₹0.96, BVPS: ₹15.87 |
INDRANIB Intrinsic Value vs Market Price — All Valuation Models
Indrayani Biotech fair value range ₹6–₹23 vs current market price ₹9.36 across 9 valuation models. See INDRANIB price to book ratio to compare market price against book value per share.
INDRANIB Intrinsic Value Analysis — Undervalued or Overvalued?
Indrayani Biotech median intrinsic value ₹15.65, current price ₹9.36 — Trading Below Calculated Value by 67.2%, margin of safety 40.2%.
What is the intrinsic value of INDRANIB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Indrayani Biotech (INDRANIB) is ₹15.65 (median value). With the current market price of ₹9.36, this represents a +67.2% variance from our estimated fair value.
The valuation range spans from ₹6.14 to ₹23.40, indicating ₹6.14 - ₹23.40.
Is INDRANIB undervalued or overvalued?
Based on our multi-method analysis, Indrayani Biotech (INDRANIB) appears to be trading below calculated value by approximately 67.2%.
INDRANIB Financial Health — Key Ratios vs Industry Benchmarks
Indrayani Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.74 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 6.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.62x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
INDRANIB Cash Flow Quality — Operating & Free Cash Flow
Indrayani Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-7 Cr | ₹-7 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-30 Cr | ₹-38 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹16 Cr | ₹-8 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹4 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |